Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials
Crossref DOI link:
Published Online: 2016-05-11
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
de Bruin, Tjerk W. A.
Funding for this research was provided by:
The design and conduct of the analysis were supported by Amylin Pharmaceuticals, a wholly owned subsidiary of AstraZeneca.